青少年起病系统性红斑狼疮青少年及成人患者抗SARS-CoV-2疫苗接种:耐受性与对疾病活动度的影响
该单中心回顾性研究纳入65例至少接种一剂抗SARS-CoV-2疫苗的青少年起病系统性红斑狼疮(JSLE)患者,其中46例完成加强针接种。轻中度不良事件发生率为66%,接种后BILAG和SLEDAI无显著变化,疾病复发率为10.8%(主要为狼疮肾炎);复发多见于接种前中等疾病活动度患者,SLEDAI≥4识别出复发风险患者,而狼疮低疾病活动状态(LLDAS)对接种后复发有保护作用。
要点
- JSLE患者接种抗SARS-CoV-2疫苗后轻中度不良事件发生率为66%,加强针后不良事件发生率与最初两剂相似。
- 接种后BILAG和SLEDAI无显著变化,疾病复发率为10.8%,主要为狼疮肾炎。
- 复发多见于接种前中等疾病活动度患者,SLEDAI≥4识别复发风险,LLDAS对接种后复发有保护作用。
核心结论
- 本研究证实JSLE患者接种抗SARS-CoV-2疫苗耐受性良好;对未处于LLDAS的患者,因存在接种后复发风险,应进行严格临床监测并审慎选择接种时机。
研究设计与样本
- 单中心回顾性研究,回顾性审查接受至少一剂任何抗SARS-CoV-2疫苗的JSLE患者临床记录,收集疾病活动度、治疗、疫苗接种及COVID-19感染数据。
主要发现
- 65例JSLE患者接受至少一剂抗SARS-CoV-2疫苗接种,46例完成加强针接种。
- 轻中度不良事件发生率为66%,主要为发热、乏力、关节肌肉痛和注射部位疼痛。
- 加强针后不良事件发生率与最初两剂后记录的发生率相似。
- 接种后BILAG和SLEDAI无显著变化。
- 免疫接种后疾病复发率为10.8%,主要为狼疮肾炎(LN);复发主要发生于免疫接种前中等疾病活动度患者,SLEDAI≥4识别出复发风险患者,LLDAS对接种后复发有保护作用。
关键数值与推荐
- 轻中度不良事件发生率为66%。
- 疾病复发率为10.8%,主要为狼疮肾炎。
- SLEDAI≥4识别复发风险患者;LLDAS对接种后复发有保护作用。
临床怎么用
- 对未处于LLDAS的JSLE患者,应进行严格临床监测并审慎选择接种时机,因存在接种后复发风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: JSLE has a severe presentation and a remitting course. Patients with JSLE carry an increased vulnerability to infections, which also act as triggers of disease flare. Thus, vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important tool in JSLE. The objective of this study is to evaluate the tolerability and the safety of anti-SARS-CoV-2 vaccination, including the booster, in a monocentric cohort of JSLE patients. METHODS: Clinical records of JSLE patients who received at least one dose of any anti-SARS-CoV-2 vaccine were retrospectively reviewed. Data about disease activity, treatment, anti-SARS-CoV-2 vaccination and COVID-19 infection were collected. RESULTS: Sixty-five JSLE patients received at least one dose of anti-SARS-CoV-2 vaccination, while 46 patients completed the schedule with the booster. The rate of mild-moderate adverse events was 66%, mainly comprising fever, fatigue, arthromyalgias and pain at injection site. The rate of adverse events after the booster was similar to that registered after the first two doses. No significant changes after SARS-CoV-2 vaccination in BILAG and SLEDAI were observed. Disease flare rate (mainly LN) after immunization was 10.8%. Flares occurred predominantly in patients with moderate disease activity before immunization; accordingly, SLEDAI ≥4 identified patients at risk of flare while Lupus Low Disease Activity State (LLDAS) plays a protective role against post-vaccination flare. CONCLUSIONS: This study confirms that anti-SARS-CoV-2 vaccination in JSLE is well tolerated; a strict clinical monitoring and a thoughtful choice of vaccination timing should be devoted to patients not in LLDAS due to the risk of post-vaccine flare.
引用
- Chighizola CB, Suardi I, Carrea G, et al. Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity. Rheumatology (Oxford). 2023. PMID: 36702464. doi:10.1093/rheumatology/kead047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。